Last reviewed · How we verify
NNC0165-1875
At a glance
| Generic name | NNC0165-1875 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity (PHASE2)
- A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NNC0165-1875 CI brief — competitive landscape report
- NNC0165-1875 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI